Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

XENE

Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XENE
DateTimeSourceHeadlineSymbolCompany
03/05/202406:01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
16/04/202422:30GlobeNewswire Inc.Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual MeetingNASDAQ:XENEXenon Pharmaceuticals Inc
05/04/202407:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
13/03/202407:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS DaysNASDAQ:XENEXenon Pharmaceuticals Inc
09/03/202410:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
09/03/202409:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
09/03/202409:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
09/03/202409:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
08/03/202411:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
08/03/202411:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
06/03/202408:01GlobeNewswire Inc.Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024NASDAQ:XENEXenon Pharmaceuticals Inc
01/03/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
01/03/202408:01GlobeNewswire Inc.Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
23/02/202408:01GlobeNewswire Inc.Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate UpdateNASDAQ:XENEXenon Pharmaceuticals Inc
15/02/202401:12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XENEXenon Pharmaceuticals Inc
09/01/202400:00GlobeNewswire Inc.Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024NASDAQ:XENEXenon Pharmaceuticals Inc
04/01/202400:30GlobeNewswire Inc.Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XENEXenon Pharmaceuticals Inc
03/01/202408:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XENEXenon Pharmaceuticals Inc
05/12/202308:16GlobeNewswire Inc.Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:XENEXenon Pharmaceuticals Inc
03/12/202304:01GlobeNewswire Inc.Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)NASDAQ:XENEXenon Pharmaceuticals Inc
01/12/202308:18Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XENEXenon Pharmaceuticals Inc
01/12/202308:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
30/11/202314:51GlobeNewswire Inc.Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public OfferingNASDAQ:XENEXenon Pharmaceuticals Inc
30/11/202309:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:XENEXenon Pharmaceuticals Inc
30/11/202308:03GlobeNewswire Inc.Xenon Pharmaceuticals Announces Proposed Public OfferingNASDAQ:XENEXenon Pharmaceuticals Inc
27/11/202323:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
27/11/202323:00GlobeNewswire Inc.Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)NASDAQ:XENEXenon Pharmaceuticals Inc
10/11/202308:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XENEXenon Pharmaceuticals Inc
10/11/202308:03GlobeNewswire Inc.Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine BiosciencesNASDAQ:XENEXenon Pharmaceuticals Inc
09/11/202308:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XENEXenon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:XENE